Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells.

Biomedical reports

Kim BB, Ko Y, Park JB.
PMID: 26623028
Biomed Rep. 2015 Nov;3(6):845-848. doi: 10.3892/br.2015.520. Epub 2015 Sep 28.

Risedronate has been used for the prevention and treatment of postmenopausal and corticosteroid-induced osteoporosis. The present study was performed to evaluate the effects of risedronate on the morphology and viability of human stem cells derived from the gingiva. Stem...

Cite
Kim BB, Ko Y, Park JB. Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells. Biomed Rep. 2015;3(6):845-848doi: 10.3892/br.2015.520.
Kim, B. B., Ko, Y., & Park, J. B. (2015). Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells. Biomedical reports, 3(6), 845-848. https://doi.org/10.3892/br.2015.520
Kim, Bo-Bae, et al. "Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells." Biomedical reports vol. 3,6 (2015): 845-848. doi: https://doi.org/10.3892/br.2015.520
Kim BB, Ko Y, Park JB. Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells. Biomed Rep. 2015 Nov;3(6):845-848. doi: 10.3892/br.2015.520. Epub 2015 Sep 28. PMID: 26623028; PMCID: PMC4660587.
Copy Download .nbib Format: NLM
Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis.

Patient preference and adherence

Calabria S, Cinconze E, Rossini M, Rossi E, Maggioni AP, Pedrini A, De Rosa M.
PMID: 27143860
Patient Prefer Adherence. 2016 Apr 19;10:523-30. doi: 10.2147/PPA.S95634. eCollection 2016.

PURPOSE: Osteoporosis is a chronic disease and an important health and social burden due to its worldwide prevalence. Literature and clinical experience report incomplete adherence to the therapy. This retrospective observational study aimed at assessing the adherence to first-line...

Cite
Calabria S, Cinconze E, Rossini M, et al. Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis. Patient Prefer Adherence. 2016;10:523-30doi: 10.2147/PPA.S95634.
Calabria, S., Cinconze, E., Rossini, M., Rossi, E., Maggioni, A. P., Pedrini, A., & De Rosa, M. (2016). Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis. Patient preference and adherence, 10523-30. https://doi.org/10.2147/PPA.S95634
Calabria, S, et al. "Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis." Patient preference and adherence vol. 10 (2016): 523-30. doi: https://doi.org/10.2147/PPA.S95634
Calabria S, Cinconze E, Rossini M, Rossi E, Maggioni AP, Pedrini A, De Rosa M. Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis. Patient Prefer Adherence. 2016 Apr 19;10:523-30. doi: 10.2147/PPA.S95634. eCollection 2016. PMID: 27143860; PMCID: PMC4844437.
Copy Download .nbib Format: NLM
Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study.

Korean journal of family medicine

Cho YH, Bae KH, Lee DR, Lee J.
PMID: 32447881
Korean J Fam Med. 2020 Sep;41(5):339-345. doi: 10.4082/kjfm.19.0110. Epub 2020 May 25.

BACKGROUND: Intermittent dosing regimens for oral risedronate (once-monthly and once-weekly) were developed for patient convenience. While several studies have reported the anti-fracture efficacy of weekly dosing, few have assessed monthly dosing. The lower efficacy of monthly dosing has been...

Cite
Cho YH, Bae KH, Lee DR, et al. Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study. Korean J Fam Med. 2020;41(5):339-345doi: 10.4082/kjfm.19.0110.
Cho, Y. H., Bae, K. H., Lee, D. R., & Lee, J. (2020). Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study. Korean journal of family medicine, 41(5), 339-345. https://doi.org/10.4082/kjfm.19.0110
Cho, Yong Ho, et al. "Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study." Korean journal of family medicine vol. 41,5 (2020): 339-345. doi: https://doi.org/10.4082/kjfm.19.0110
Cho YH, Bae KH, Lee DR, Lee J. Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study. Korean J Fam Med. 2020 Sep;41(5):339-345. doi: 10.4082/kjfm.19.0110. Epub 2020 May 25. PMID: 32447881; PMCID: PMC7509122.
Copy Download .nbib Format: NLM
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.

Investigational new drugs

Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S.
PMID: 33300108
Invest New Drugs. 2021 Jun;39(3):644-657. doi: 10.1007/s10637-020-01040-y. Epub 2020 Dec 09.

Objectives Malignant pleural mesothelioma (MPM) is an occupational disease mainly due to asbestos exposure. Effective therapies for MPM are lacking, making this tumour type a fatal disease. Materials and Methods In order to meet this need and in view...

Cite
Dell'Anno I, Martin SA, Barbarino M, et al. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. Invest New Drugs. 2020;39(3):644-657doi: 10.1007/s10637-020-01040-y.
Dell'Anno, I., Martin, S. A., Barbarino, M., Melani, A., Silvestri, R., Bottaro, M., Paolicchi, E., Corrado, A., Cipollini, M., Melaiu, O., Giordano, A., Luzzi, L., Gemignani, F., & Landi, S. (2021). Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. Investigational new drugs, 39(3), 644-657. https://doi.org/10.1007/s10637-020-01040-y
Dell'Anno, Irene, et al. "Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma." Investigational new drugs vol. 39,3 (2021): 644-657. doi: https://doi.org/10.1007/s10637-020-01040-y
Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. Invest New Drugs. 2021 Jun;39(3):644-657. doi: 10.1007/s10637-020-01040-y. Epub 2020 Dec 09. PMID: 33300108; PMCID: PMC8068714.
Copy Download .nbib Format: NLM
Retraction Note to: Anti-Fracture Efficacy of Risedronic Acid in Men : A Meta-Analysis of Randomized Controlled Trials.

Clinical drug investigation

Zhong ZM, Chen JT.
PMID: 33507528
Clin Drug Investig. 2021 Feb;41(2):199. doi: 10.1007/s40261-020-00999-z.

No abstract available.

Cite
Zhong ZM, Chen JT. Retraction Note to: Anti-Fracture Efficacy of Risedronic Acid in Men : A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2021;41(2):199doi: 10.1007/s40261-020-00999-z.
Zhong, Z. M., & Chen, J. T. (2021). Retraction Note to: Anti-Fracture Efficacy of Risedronic Acid in Men : A Meta-Analysis of Randomized Controlled Trials. Clinical drug investigation, 41(2), 199. https://doi.org/10.1007/s40261-020-00999-z
Zhong, Zhao-Ming, and Chen, Jian-Ting. "Retraction Note to: Anti-Fracture Efficacy of Risedronic Acid in Men : A Meta-Analysis of Randomized Controlled Trials." Clinical drug investigation vol. 41,2 (2021): 199. doi: https://doi.org/10.1007/s40261-020-00999-z
Zhong ZM, Chen JT. Retraction Note to: Anti-Fracture Efficacy of Risedronic Acid in Men : A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2021 Feb;41(2):199. doi: 10.1007/s40261-020-00999-z. PMID: 33507528.
Copy Download .nbib Format: NLM
A Diversified Spectrometric and Molecular Docking Technique to Biophysical Study of Interaction between Bovine Serum Albumin and Sodium Salt of Risedronic Acid, a Bisphosphonate for Skeletal Disorders.

Bioinorganic chemistry and applications

Manjushree M, Revanasiddappa HD.
PMID: 30050563
Bioinorg Chem Appl. 2018 Jun 28;2018:6954951. doi: 10.1155/2018/6954951. eCollection 2018.

The binding interaction between bovine serum albumin (BSA) and sodium salt of risedronic acid (RSN) was studied by using the FT-IR (Fourier transform infrared), UV-Vis (ultraviolet-visible), fluorescence (emission and synchronous), CD (circular dichroism) spectrometric, and computational (molecular docking) techniques...

Cite
Manjushree M, Revanasiddappa HD. A Diversified Spectrometric and Molecular Docking Technique to Biophysical Study of Interaction between Bovine Serum Albumin and Sodium Salt of Risedronic Acid, a Bisphosphonate for Skeletal Disorders. Bioinorg Chem Appl. 2018;2018:6954951doi: 10.1155/2018/6954951.
Manjushree, M., & Revanasiddappa, H. D. (2018). A Diversified Spectrometric and Molecular Docking Technique to Biophysical Study of Interaction between Bovine Serum Albumin and Sodium Salt of Risedronic Acid, a Bisphosphonate for Skeletal Disorders. Bioinorganic chemistry and applications, 20186954951. https://doi.org/10.1155/2018/6954951
Manjushree, M, and Revanasiddappa, Hosakere D. "A Diversified Spectrometric and Molecular Docking Technique to Biophysical Study of Interaction between Bovine Serum Albumin and Sodium Salt of Risedronic Acid, a Bisphosphonate for Skeletal Disorders." Bioinorganic chemistry and applications vol. 2018 (2018): 6954951. doi: https://doi.org/10.1155/2018/6954951
Manjushree M, Revanasiddappa HD. A Diversified Spectrometric and Molecular Docking Technique to Biophysical Study of Interaction between Bovine Serum Albumin and Sodium Salt of Risedronic Acid, a Bisphosphonate for Skeletal Disorders. Bioinorg Chem Appl. 2018 Jun 28;2018:6954951. doi: 10.1155/2018/6954951. eCollection 2018. PMID: 30050563; PMCID: PMC6046188.
Copy Download .nbib Format: NLM
The diagnosis and treatment of primary osteoporosis according to current guidelines.

Deutsches Arzteblatt international

Baum E, Peters KM.
PMID: 19471676
Dtsch Arztebl Int. 2008 Aug;105(33):573-81; quiz 581-2. doi: 10.3238/arztebl.2008.0573. Epub 2008 Aug 15.

INTRODUCTION: Osteoporosis is the most common generalized disease of the skeleton, yet it is markedly undertreated in Germany.METHODS: Selective literature review on the basis of the current German guidelines regarding the prevention, diagnosis, and treatment of osteoporosis in postmenopausal...

Cite
Baum E, Peters KM. The diagnosis and treatment of primary osteoporosis according to current guidelines. Dtsch Arztebl Int. 2008;105(33):573-81; quiz 581-2doi: 10.3238/arztebl.2008.0573.
Baum, E., & Peters, K. M. (2008). The diagnosis and treatment of primary osteoporosis according to current guidelines. Deutsches Arzteblatt international, 105(33), 573-81; quiz 581-2. https://doi.org/10.3238/arztebl.2008.0573
Baum, Erika, and Peters, Klaus M. "The diagnosis and treatment of primary osteoporosis according to current guidelines." Deutsches Arzteblatt international vol. 105,33 (2008): 573-81; quiz 581-2. doi: https://doi.org/10.3238/arztebl.2008.0573
Baum E, Peters KM. The diagnosis and treatment of primary osteoporosis according to current guidelines. Dtsch Arztebl Int. 2008 Aug;105(33):573-81; quiz 581-2. doi: 10.3238/arztebl.2008.0573. Epub 2008 Aug 15. PMID: 19471676; PMCID: PMC2680556.
Copy Download .nbib Format: NLM
Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?.

Drugs in context

Statham L, Abdy S, Aspray TJ.
PMID: 32426015
Drugs Context. 2020 May 08;9. doi: 10.7573/dic.2020-1-3. eCollection 2020.

BACKGROUND: On stopping bisphosphonate treatment, bone resorption may increase before evidence of a decrease in bone density. Offset of bisphosphonate effect may therefore be monitored by measuring C-terminal telopeptide (CTX) following long-term bisphosphonate treatment to inform clinical decisions on...

Cite
Statham L, Abdy S, Aspray TJ. Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?. Drugs Context. 2020;9doi: 10.7573/dic.2020-1-3.
Statham, L., Abdy, S., & Aspray, T. J. (2020). Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?. Drugs in context, 9. https://doi.org/10.7573/dic.2020-1-3
Statham, Louise, et al. "Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?." Drugs in context vol. 9 (2020). doi: https://doi.org/10.7573/dic.2020-1-3
Statham L, Abdy S, Aspray TJ. Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?. Drugs Context. 2020 May 08;9. doi: 10.7573/dic.2020-1-3. eCollection 2020. PMID: 32426015; PMCID: PMC7216784.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries